Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

The data showed patients who took GLP-1 drugs had a much lower risk of developing cancer than those who took DDP-4s.

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...

About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ...

How a new Trump plan could make science ‘a political football’ The NIH is already in turmoil. Billlions of dol ...

Hundreds of thousands of people around the world are now on weight loss drugs like Wegovy, known as GLP-1s. The food industry is taking notice too, with big companies leaning into more nutritional ...

Scientists at Sweden’s Karolinska Institutet have discovered a promising new way to tackle obesity and its related conditions ...